Angiomax Patent Term Extension: Will Second Time Be The Charm?
This article was originally published in The Pink Sheet Daily
Executive Summary
A judge, interpreting the patent statute "liberally," again orders PTO to find that The Medicine Company met the deadline for filing its application for patent term extension.
You may also be interested in...
The Medicines Company Is Almost Ready To Celebrate Angiomax Patent Term Extension
Studies of additional indications for the product may resume as the Patent and Trademark Office assesses the potential length of the extension, which could protect the product until mid-2015.
The Medicines Company Is Almost Ready To Celebrate Angiomax Patent Term Extension
Studies of additional indications for the product may resume as the Patent and Trademark Office assesses the potential length of the extension, which could protect the product until mid-2015.
Legal News, In Brief: Copaxone, AngioMax, Cipro, Botox, OxyContin
Teva Wins Ruling On Copaxone Patents